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An epigenome-wide study of obesity in
African American youth and young adults:
novel findings, replication in neutrophils,
and relationship with gene expression
Xiaoling Wang1* , Yue Pan1, Haidong Zhu1, Guang Hao1, Yisong Huang1, Vernon Barnes1, Huidong Shi2,
Harold Snieder3, James Pankow4, Kari North5, Megan Grove6, Weihua Guan4, Ellen Demerath4, Yanbin Dong1
and Shaoyong Su1
Abstract
Background: We conducted an epigenome-wide association study (EWAS) on obesity in healthy youth and young
adults and further examined to what extent identified signals influenced gene expression and were independent of
cell type composition and obesity-related cardio-metabolic risk factors. Genome-wide DNA methylation data from
leukocytes were obtained from 700 African Americans aged 14–36. We also measured genome-wide DNA methylation
data from neutrophils as well as genome-wide gene expression data from leukocytes in a subset of samples (n = 188).
Results: The EWAS identified 76 obesity-related CpG sites in leukocytes with p < 1 × 10−7. In silico replication in the
ARIC study of 2097 African Americans aged 47–70 validated 54 CpG sites. Out of the 54 CpG sites, 29 associations with
obesity were novel and 37 were replicated in neutrophils. Fifty one CpG sites were associated with at least one cardio-
metabolic risk factor; however, the number reduced to 9 after adjustment for obesity. Sixteen CpG sites were associated
with expression of 17 genes in cis, of which 5 genes displayed differential expression between obese cases and lean
controls. We also replicated 71.5% of obesity-related CpG sites previously reported.
Conclusion: In this study of youth and young adults, we identified 29 novel CpG sites associated with obesity and
replicated the majority of the CpG sites previously identified. We further demonstrated that the majority of the obesity-
related CpG sites in leukocytes were not driven by cell composition or obesity-related cardio-metabolic risk factors. We
also provided the direct link between DNA methylation-gene expression-obesity for 5 genes.
Keywords: DNA methylation, Youth, African Americans, Obesity, Leukocytes, Neutrophils
Background
Obesity is a complex disease resulting from interactions
between genes and environmental factors that can be
modified and/or mediated by epigenetic changes. DNA
methylation is a pivotal and stable epigenetic mechanism,
and DNA methylation levels at particular loci have been
associated with obesity and its related cardio-metabolic
traits [1]. Recently, four large-scale epigenome-wide
association studies (EWAS) [2–5] in middle-aged and
older adults identified multiple DNA methylation loci in
blood leukocytes that were associated with body mass
index (BMI). However, the high prevalence of obesity
comorbidities and use of medications in middle-aged or
older populations may hide or bias obesity-related DNA
methylation changes. For this reason, we investigated 700
healthy African American youth and young adults. With
genome-wide DNA methylation data from leukocytes in
the full data set and genome-wide DNA methylation data
from purified neutrophils and genome-wide gene expres-
sion data from leukocytes in a subset of 188 subjects, the
present study has three objectives. First, we conducted an
EWAS of obesity in youth and young adults to identify
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new signals and further validate the findings with replica-
tion in an independent cohort of 2097 middle-aged
African Americans from the Atherosclerosis Risk in
Communities (ARIC) study [2]. Second, for these obesity-
related DNA methylation loci, we checked whether the
associations can be replicated in one purified cell type
(neutrophils), whether the associations were driven by
obesity-related cardio-metabolic traits, and whether the
DNA methylation status of these loci was associated with
gene expressions. Third, we examined to what extent we
can replicate the findings previously reported in middle-
aged and older adults. The identification of obesity-related
DNA methylation changes in youth and young adult may
provide new insights into the mechanisms linking obesity
to associated clinical conditions at the early stages of the




A total of 700 African American youths and young
adults aged 14–36 were included in the current study.
These subjects were participants from 3 existing cohorts
(for details, see Additional file 1): the Epigenetic Basis of
Obesity-Induced Cardiovascular Disease and Type 2
Diabetes (EpiGO) study [6] (96 obese [BMI percentile ≥
95%] vs. 92 lean controls [BMI percentile ≤ 50%] aged
14–20), the LACHY study [7] (284 participants from the
general population aged 14–18), and the BP stress study
[8] (228 participants from the general population aged
18–36). All of these participants were free of chronic or
acute disease and not on daily prescription medication
for treatment of diseases. All participants were recruited
from the southeastern USA. Height and weight were
measured by standard methods using a wall-mounted
stadiometer and a scale, respectively. BMI was calculated
as weight/height2, and BMI percentile was calculated
according to their age, sex, height, and weight. These
studies were approved by the Institutional Review Board
of Augusta University and performed following the
guidelines of the Declaration of Helsinki. Written
informed consent was provided by all participants or by
their parents if they were less than 18 years.
DNA extraction and genome-wide DNA methylation
For the participants from the EpiGO study, DNA was
extracted from both peripheral leukocytes and neutrophils
using the QIAamp DNA Mini Kit (QIAGEN). Peripheral
neutrophils were obtained using the approach previously
described [9]. For the other participants, DNA was
extracted from stored buffy coats using the same kit.
Genome-wide DNA methylation levels of all these sam-
ples were analyzed by the Illumina Infinium Human
Methylation 450K Beadchip (Illumina Inc.). The Minfi
package [10] and CPACOR (incorporating Control Probe
Adjustment and reduction of global CORrelation) package
[11] were used for initial quantification, data preprocess-
ing, and quality control (QC). The key QC steps included
the following: (1) Detectable probes were defined as the
probes with detection p value < 1 × 10−16 in more than
95% samples; (2) Detectable samples were defined as the
samples with more than 95% CpG sites having a detection
p value < 1 × 10−16 and correct classification of gender
based on the genome-wide DNA methylation data; (3)
Probes on the X and Y chromosomes and the 65 SNP
markers were excluded; (4) Illumina background correc-
tion and quantile normalization were applied to all inten-
sity values, and beta value was further calculated and used
as the index of CpG methylation levels; (5) A principal
component analysis (PCA) of the control probe intensities
(excluding negative control probes) was performed and
the resulting PCs 1 to 30 were stored; (6) White blood cell
sub-populations were estimated using the approach
described by Houseman et al. [12]; and (7) A linear regres-
sion model was conducted for each CpG site with DNA
methylation level as the dependent variable and the 30
PCs from the control probe intensities as well as the
estimated cell compositions as the independent variables.
The residuals were calculated and used as indices of DNA
methylation levels in further analysis. The above steps
were conducted for each cohort separately.
RNA extraction and genome-wide gene expression assays
For the participants of the EpiGO study, RNA samples
were extracted from the peripheral leukocytes stored in
the RNA cell protection reagents (QIAGEN Inc.) using
the QIAamp RNA mini Kit (QIAGEN Inc.). RNA
concentration and purity were evaluated on a NanoDrop
spectrophotometer 2000 (Thermo Scientific Inc.). RNA
integrity (RIN) was evaluated on a Bioanalyzer 2100
(Agilent Inc.). The RIN scores of all these samples were
greater than 8, indicating the high quality of RNA.
Genome-wide gene expression data were obtained using
the Illumina HumanHT-12 v4 Expression BeadChip (Illu-
mina Inc). This chip targets more than 48,000 probes that
provide genome-wide coverage of well-characterized
genes, gene candidates, and splice variants. The Genome-
Studio Gene Expression Module (Illumina Inc.) was used
for initial quantification, and the lumi package [13] was
used for data preprocessing and QC. The key QC steps in-
cluded the following: (1) Probes with detection p value <
0.05 in more than 50% of the samples were defined as
“present”; (2) Log transformation and quartile
normalization were applied to the gene expression data;
and (3) A linear regression model was conducted for each
probe with gene expression level as the dependent variable
and batches (16 batches with 12 samples in each batch) as
the independent variables. The residuals were calculated
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and used as the indices of gene expression levels in further
analysis.
Statistical analysis
The R package Limma [14] was used for the identification
of differentially methylated CpG sites and differentially
expressed genes related to the obesity phenotypes.
For DNA methylation analysis on peripheral leukocytes,
the residual derived from the regression of each single
CpG site methylation level (beta) on cell compositions
and PCs from the control probes was used as dependent
variable with age and sex as covariates. The test of interest
was group (obese vs. lean) in the EpiGO study and BMI in
the LACHY and BP stress cohort. Meta-analysis across
the three cohorts was conducted using METAL [15] by
converting the direction of effect and p value observed in
each study into a signed Z score. This approach is very
flexible and allows results to be combined when the β-co-
efficients and standard errors from individual studies are
in different units. To account for multiple testing, a stand-
ard Bonferroni correction for the 473,788 CpG sites gives
p < 1 × 10−07 as the significance threshold.
For DNA methylation analysis on peripheral neutrophils,
the residual derived from the regression of each single CpG
site methylation level on PCs from the control probes was
used as dependent variable with age and sex as covariates.
The test of interest was group (obese vs. lean).
For gene expression analysis on peripheral leukocytes,
the residual derived from the regression of each probe gene
expression level on batches was used as dependent variable
with age and sex as covariates. The test of interest was
group (obese vs. lean).
The differentially methylated CpG sites identified for
obesity and BMI in peripheral leukocytes with a p
value< 1 × 10−07 were carried forward for replication in
the African American participants of the ARIC study [2]
(n = 2097, 64% females, age range from 47 to 70).
Leukocyte DNA and the same Illumina 450K platform
for methylation analysis were used in ARIC study. Repli-
cation was defined as consistent direction of the β-
coefficient and FDR < 0.05 in the BMI-related CpG sites
from the ARIC study. The replicated CpG sites were
taken forward in the following analyses: First, they were
checked in obesity-related CpGs identified from neutro-
phils. Replication was defined as consistent direction of
the β-coefficient and FDR< 0.05 in neutrophils. Second,
their associations with seven cardio-metabolic traits in-
cluding SBP, fasting glucose, fasting insulin, fasting tri-
glycerides (TG), fasting total cholesterol (TC), fasting
HDL-cholesterol (HDLC), and fasting LDL-cholesterol
(LDLC) were tested in EpiGO and LACHY cohorts with
and without the adjustment of obesity status/BMI. A p
value < 0.05 was defined as significant. Third, cis-regula-
tion of these CpG sites of gene expression (within ±
250 kb of the CpG sites) was explored. Partial correl-
ation of gene expression and DNA methylation was con-
ducted with age, gender, and group (obese vs. lean) as
covariates. A Bonferroni corrected p value < 0.05 accord-
ing to the number of genes tested for each CpG site
(range from 0 to 28) was defined as significant correl-
ation. Obesity-related differentially expressed genes were
defined as genes with their expression levels showing
significant difference between obese cases and lean con-
trols at p value < 0.05.
Pathway enrichment analysis was conducted for the
genome-wide DNA methylation obtained from leukocytes
using gene set enrichment analysis (GSEA) [16]. GSEA
was performed on an unfiltered, ranked list of genes
(ranked by the p values without consideration of direc-
tions), and a running-sum statistic was used to determine
the enrichment of an a priori defined gene sets (pathways)
based on the gene ranks. Statistical significance of pathway
enrichment scores were ascertained by permutation test-
ing over size-matched random gene sets and multiple test-
ing was controlled by the false discovery rate (FDR). A
FDR of 5% was used. Kyoto Encyclopedia of Genes and
Genomes (KEGG) gene sets were used as the reference
gene sets. The CpG site showing the most significant p
value within a gene was used to represent the DNA
methylation level of the gene.
We also checked whether we could replicate previously
identified obesity-related CpG sites (n = 277) in our
current study of youth and young adult [2–5]. Replication
was defined as a consistent direction of the β-coefficient
and FDR < 0.05.
Results
Discovery meta-analysis in the youth and young adult
Table 1 lists the general characteristics of the subjects. We
identified 76 CpG sites significantly associated (p < 1 × 10
−07) with obesity in the meta-analysis of the three cohorts
(Manhattan and QQ-plot, Fig. 1; Additional file 2: Table
S1). Obesity was positively associated with the methylation
of 65 CpG sites and negatively associated with the methy-
lation of 11 CpG sites. The top CpG site (cg12170787, p =
1.13 × 10−16) locates in the intron 5 of the SBNO2 gene
(Strawberry Notch Homolog 2). Two more CpG sites
(cg18608055, p = 3.69 × 10−16; cg07573872, p = 1.12 × 10
−09) locating in the same region also passed the threshold
for genome-wide significance. CpG site cg07573872 is lo-
cated in a CpG island shore region and has been reported
to be associated with BMI previously [2]. CpG sites
cg18608055 and cg12170787 are 4524 bp and 4623 bp
away from cg07573872 (Additional file 3: Figure S1). The
SBNO2 gene is expressed in peripheral leukocytes and is a
key player in the IL-10-regulated anti-inflammatory sig-
naling pathway [17].
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In silico replication with ARIC study
Of the 76 CpG sites significantly associated with obesity in
our discovery meta-analysis, 54 replicated (FDR < 0.05) in
the ARIC study (Table 2), of which 33 survived Bonferroni
correction (p < 6.58 × 10−4). These 54 CpG sites annotated
to 45 genes. In addition to SBNO2 which exhibits 3 signifi-
cant CpG sites, SOCS3 (suppressor of cytokine signaling
3: cg18181703, cg04610187, and cg10508317), CISH
(Cytoking-Inducible Src-Homology 2 –containing protein:
cg21585138 and cg23005227), and VMP1 (Vacuole Mem-
brane Protein: cg16936953, cg12054453, cg24174557,
cg18942579, and cg010409343) also have 2 or more sig-
nificant CpG sites. The locations of these CpG sites within
each gene and their correlations were provided in
Additional file 3: Figure S1. Out of the 54 CpG sites asso-
ciated with obesity, 29 CpG sites (annotated to 25 genes)
were novel signals (highlighted in gray in Table 2).
Replication of obesity-related CpG sites identified from
mixed cells in purified neutrophils
The 54 CpG sites were taken forward to check whether
the associations with obesity could be validated in one
purified cell type: neutrophils. The results were listed in
Additional file 2: Table S2. Thirty-seven CpG sites were
found to be associated with obesity in neutrophils (FDR <
0.05 and consistent directions of effect), confirming that
for the majority of the CpG sites (68.5%), the significant
associations with obesity are not driven by potential cell
compositions in leukocytes. For the 17 CpG sites that
were not validated in neutrophils, it is difficult to deter-
mine whether these signals are driven by cell composi-
tions or that neutrophils are not the biologically relevant
cell type to target. The fact that 6 of the 17 CpG sites were
hypermethylated (i.e., beta > 0.8) in neutrophils compared
with 0 in the 37 replicated CpG sites (p = 1.2E-4) indicated
that at least for some of the obesity-related CpG sites
which could not be validated in neutrophils, neutrophils
might not be the relevant cell type to target.
Association with cardio-metabolic phenotypes
We examined the associations between the 54 replicated
CpG sites and 7 cardiometabolic traits (SBP, fasting insu-
lin, fasting glucose, fasting lipid panel including TG, TC,
HDLC, and LDLC). Without the adjustment of obesity or
BMI, we observed 148 significant associations (p < 0.05,
Additional file 2: Table S3) with 39 for SBP, 45 for insulin,
1 for glucose, 14 for TG, 5 for TC, 25 for HDLC, and 19
for LDLC. CpGs that were significantly associated with
higher SBP, insulin, glucose, TG, TC, and LDLC were also
associated with higher BMI levels. For HDLC, CpGs were
associated with lower BMI levels (Fig. 2). After the adjust-
ment of obesity or BMI, only 11 associations remained sig-
nificant (Additional file 2: Table S4). The results indicate
that the majority of the associations of these CpG sites
with cardiometabolic phenotypes are driven by obesity.
Gene expression analyses
Of the 54 CpG sites, 16 were significantly associated
with expression of 17 unique genes in cis (Bonferroni
corrected p value < 0.05) (Additional file 2: Table S5).
Table 1 General characteristics of the subjects
General characteristics EpiGO LACHY BP stress
cohortLean Obese
N 92 96 284 228
Female (%) 50.0 51.0 50.0 57.5
Age (years) 17.7 ± 1.7 17.7 ± 1.8 16.2 ± 1.3 27.8 ± 3.3
Age range (years) 14.0–20.9 14.1–21.0 13.8–19.0 18.9–35.6
BMI (kg/m2) 18.8 ± 1.3 39.8 ± 6.8 24.1 ± 5.6 31.4 ± 8.6
BMI range (kg/m2) 15.0–21.7 28.1–70.1 16.4–45.9 17.6–59.6
BMI percentile (%) 18.7 ± 11.0 98.8 ± 1.1 65.7 ± 28.3 –
BMI percentile range (%) 0.8–41.7 95.0–99.9 2.3–99.7 –
Fig. 1 Left panel: Manhattan plot of the genome-wide DNA methylation analysis in youths and young adults. The dotted line indicates the
Bonferroni threshold of 1E−07 for significance. Right panel: QQ plot of the genome-wide DNA methylation analysis in youth and young adults
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Furthermore, of these 17 genes, the expression levels of
5 genes were significantly associated with obesity (p <
0.05) (Additional file 2: Table S5). Figure 3 shows the
corresponding relationships between DNA methylation
and gene expression for these 5 genes. With the excep-
tion of the correlation between cg06178669 and
HRASLS2 (HRAS-like suppressor 2), increased methyla-
tion was associated with decreased gene expressions. For
Table 2 Validated CpG sites in the ARIC study
Newly discovered associations are highlighted in gray
*“+” indicates that DNA methylation levels increase with obesity status or BMI. The order is Epigo, LACHY, and BP stress cohort
**DNA methylation changes with 1 unit increase in BMI
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SOCS3, CISH, PIM3 (Pim-3 proto-oncogene, serine/
threonine kinase), and KLF4 (Kruppel-like factor 4),
obesity was associated with decreased methylation and
increased gene expression, while for HRASLS2, obesity
was associated with decreased methylation and
decreased gene expression (Additional file 2: Table S5).
Pathway analyses
The pathway analyses yielded significant (FDR < 0.05) en-
richment of 33 KEGG pathways for obesity-related DNA
methylation changes in peripheral leukocytes
(Additional file 2: Table S6). These pathways represent pro-
cesses involved in inflammatory pathways (e.g., cell
adhesion molecules, JAK-STAT signaling pathway, intes-
tinal immune network for IGA production), autoimmune
response (e.g., type 1 diabetes, allograft rejection, graft
versus host disease), and obesity-related comorbidities (e.g.
type 2 diabetes, vascular smooth muscle contraction, can-
cer, and asthma).
Replication of previously reported CpG sites for obesity in
middle-aged and elderly adults
We attempted to replicate the previously reported CpG
sites for obesity. At the time this study was conducted, 4
large EWASs (with replication cohorts) for obesity were
available: the ARIC study by Demerath E et al. [2]
(reported 37 CpG sites), the Cardiogenics Consortium
study by Dick K et al. [4] (reported 3 CpG sites), the
GOLDN study by Aslibekyan S et al. [5] (reported 8
CpG sites), and the study reported by Wahl S et al. [3]
(reported 254 CpG sites). These 4 studies resulted in
277 unique CpG sites associated with obesity. Out of
these 277 CpG sites, 198 (71.5%) could be replicated
with consistent direction of effect and a FDR < 0.05 in
our study (Additional file 2: Table S7), indicating that
majority of the obesity-related CpG sites identified in
middle-aged and elderly adults already show changes in
youth and young adulthood.
Discussion
In this epigenome-wide association study of African
American youth and young adults, we identified 29
novel CpG sites associated with obesity and the repli-
cated majority of the CpG sites previously identified in
middle-aged and older adults. We further demonstrated
that majority of the obesity-related CpG sites identified
from leukocytes are not driven by cell compositions or
obesity-related cardio-metabolic risk factors. We also
provided direct links between DNA methylation, gene
expression, and obesity status for 7 CpG sites in 5 genes.
Unlike genetic markers that are the same in all cells
and unlikely to change over a lifetime, epigenetic regula-
tion is tissue specific and plastic (i.e., findings may re-
flect the consequence rather than the cause of the
disease) [18]. In addition to availability, the choice of
leukocytes in this study as well as in the previous
epigenome-wide association studies of obesity in middle-
aged and elder people is based on the fact that obesity is
characterized by a state of chronic, low-grade inflamma-
tion [19]. With the established role of epigenetic regula-
tion in shaping the immune and inflammatory response
[20], identification of the epigenetic markers specifically
involved in obesity-induced inflammation has the poten-
tial to provide novel insight into the pathogenesis of
obesity-related disorders. The choice of leukocytes also
assumes that the observed epigenetic changes will reflect
consequences rather than causes of obesity. Although
the cross-sectional design of the current and previous
studies [2–5] does not provide information on the direc-
tion of causality, the Mendelian randomization model
Fig. 2 Manhattan plot depicting the − log10(p values) and effect direction (respectively to obesity) of the associations between the 55 replicated
CpG sites and each cardiometabolic phenotype. The lines indicate the threshold of 0.05 for significance
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used in one [3] of the previous adult studies strongly
suggested that obesity-related DNA methylation changes
identified in peripheral leukocytes are predominately the
consequence rather than the cause of obesity. One con-
cern in analyzing epigenetic changes in peripheral
leukocytes in obese individuals is that the effect of obes-
ity itself on the immune system can be hidden or biased
by the coexistence of obesity-related diseases and the
use of medication, which is very common in middle-
aged and elderly individuals. To avoid this problem, in
this study, we focused on youth and young adults. This
is a population having shown obesity-related metabolic
risk that has not developed into clinical disease yet. We
did observe that many obesity-related CpG sites were as-
sociated with cardiometabolic traits. However, after the
adjustment of obesity, this number decreased dramatic-
ally, indicating that a large majority of the associations
of these CpG sites with cardiometabolic phenotypes is
driven by obesity.
In comparing with the previous studies in middle-aged
adults and elderly [2–5], we identified 29 novel CpG
sites (annotated to 25 genes). We were also able to
present triangular relationships between DNA
methylation, gene expression, and obesity at 5 genes in-
cluding SOCS3, CISH, PIM3, KLF4, and HRASLS2. With
the exception of HARSLS2, obesity was associated with
decreased DNA methylation level and increased gene
expressions. Interestingly, both SOCS3 and CISH are
involved in the JAK-STAT signaling pathway and are the
key negative regulators of the activation of this pathway
[21]. The JAK-STAT signaling pathway is activated
during inflammation and used by a variety of cytokines.
The JAK-STAT signaling pathway activates its own
suppressors: suppressors of cytokine signaling (SOCS)
Fig. 3 Partial correlations between DNA methylation and gene expression. Covariates included age, sex, and obesity status. Gray dots represent
the lean group and black diamonds represent the obese group. For the SOCS3 gene, similar correlation was observed for cg04610187 (r = − 0.20,
p = 1.77E−03); for the CISH gene, similar correlation was observed for cg23005227 (r = − 0.21, p = 7.14E−03)
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molecules including SOCS1-7 and CISH. This negative
feedback control is essential for the effective dissipation
of cytokine signaling to prevent excessive inflammation
and detrimental effect on other signaling pathways.
However, the increased levels of SOCS proteins can in-
duce insulin resistance in peripheral organs [22] and lep-
tin resistance in the central nervous system [23]. There
are very limited studies on PIM3, KLF4, and HARSLS2.
However, PIM1, a protein from the same family and
structurally and functionally similar to PIM3, is also pri-
marily involved in the JAK/STAT signaling pathway.
PIM-1 transcription is initiated by STAT factors and can
also bind to regulators of the JAK/STAT pathway, result-
ing in a negative feedback loop [24]. Taken together, the
activation of the JAK/STAT signaling pathway in obesity
transcriptionally upregulates its own suppressors
through DNA methylation mechanisms. On the one
hand, the increased production of negative regulators
can prevent excessive inflammation, while on the other
hand, these increased negative feedback products may
increase the risk of obesity-related disorders, a compen-
satory mechanism that has been observed in the devel-
opment of many diseases.
Our study in healthy youth and young adults also repli-
cated 71.5% of obesity-related CpG sites previously re-
ported in middle-aged and elderly adults, indicating that
the majority of the obesity-related CpG sites already show
changes in adolescence. It will be interesting to find out
the age of onset of these changes. In a recent study explor-
ing this question on the first EWAS-identified gene
(HIF3A), Pan et al. [25] observed that DNA methylation
levels at the three previously described HIF3A CpG sites
were already associated with greater weight and adiposity
at birth. On the other hand, the strong consistency of
obesity-related DNA methylation signals across ethnic
groups (African Americans in this study comparing with
Caucasians, Asians, and African Americans in previous
studies) and age emphasizes the importance of conducting
large-scale epigenome-wide meta-analysis similar to what
has been done in the GWAS. This action will discover
more obesity-related epigenome-wide changes and enable
the recognition of the overall picture of the role of DNA
methylation in obesity and its related disorders.
One possible concern in these EWAS studies on obes-
ity using peripheral blood is the heterogeneity of leuko-
cytes since different cell populations have distinct
epigenetic signatures [26]. This concern was dramatically
reduced with the development of algorithms estimating
the cell subset compositions based on genome-wide
DNA methylation data [12]. Our study further confirms
this through successfully replication of 68.5% of the
obesity-related CpG sites from leukocytes in one purified
cell type: neutrophils. The reason that neutrophils were
selected is that previous studies including ours [9, 27]
have observed that obesity is consistently associated with
neutrophilia, manifesting not only by elevated neutrophil
count but also increased percentage. However, we be-
lieve that replication of the findings from leukocytes in a
variety of other single cell types remains important to
guide further functional in vitro studies.
Several limitations to the present study need to be rec-
ognized. First, although the study by Wahl S et al. [3] in
adults have shown that obesity-related DNA methylation
changes identified in peripheral leukocytes are predom-
inately the consequence rather than the cause of obesity,
we cannot test the direction of the causality of these
newly identified obesity-related CpG sites in youth and
young adults due to the cross-sectional design and the
lack of genotype data. Second, although 71% of the
signals from the discovery cohort were validated in the
replication cohort, the lack of replication of other signals
might be due to the age difference between the discovery
cohort and the replication cohort. Third, due to the lack
of genotype data, we cannot adjust the potential bias
resulted from ancestry compositions.
Conclusion
In summary, this EWAS study in healthy youth and
young adult confirmed the majority of previously identi-
fied obesity-related DNA methylation loci in middle-
aged and elderly adults and identified 29 novel CpG sites
associated with obesity. The findings from the current
study have the potential to enable development of new
strategies for early prevention and treatment.
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